About Alvotech
https://www.alvotech.comAlvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland.
CEO
Vilhelm Robert Wessman
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public June 16, 2022
Method of going public SPAC
Full time employees 1,012
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 4
Debt To Equity 1
Price To Earnings 3
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
OAKTREE CAPITAL MANAGEMENT LP
Shares:4.67M
Value:$2.38M
SERENGETI ASSET MANAGEMENT LP
Shares:400K
Value:$204K
LINDEN ADVISORS LP
Shares:252.88K
Value:$128.97K
Summary
% Of Shares Owned 1.84%
Total Number Of Holders 14
Showing Top 3 of 14
Market Cap $191.77 M
52w High $1.98
52w Low $0.51
P/E 0
Volume 300
Outstanding Shares 299.64M
About Alvotech
https://www.alvotech.comAlvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $113.95M ▼ | $77.56M ▼ | $-5.22M ▼ | -4.58% ▼ | $-0.02 ▼ | $3.69M ▼ |
| Q2-2025 | $173.24M ▲ | $81.36M ▲ | $32.04M ▼ | 18.49% ▼ | $0.11 ▼ | $51.74M ▼ |
| Q1-2025 | $132.76M ▼ | $56.74M ▼ | $109.68M ▲ | 82.61% ▲ | $0.39 ▲ | $137.22M ▲ |
| Q4-2024 | $151.21M ▲ | $57.4M ▲ | $-66.97M ▼ | -44.29% ▼ | $-0.22 ▼ | $-119.98M ▼ |
| Q3-2024 | $102.89M | $50.35M | $-11.39M | -11.07% | $-0.04 | $138.22M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $42.85M ▼ | $1.41B ▲ | $1.59B ▲ | $-176.76M ▼ |
| Q2-2025 | $151.45M ▲ | $1.39B ▲ | $1.57B ▲ | $-173.33M ▲ |
| Q1-2025 | $38.54M ▼ | $1.25B ▲ | $1.55B ▼ | $-302.29M ▲ |
| Q4-2024 | $51.43M ▼ | $1.22B ▼ | $1.63B ▲ | $-412.77M ▼ |
| Q3-2024 | $118.27M | $1.23B | $1.58B | $-343.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.25M ▼ | $-55.58M ▼ | $-39.45M ▼ | $-13.24M ▼ | $-108.6M ▼ | $-74.5M ▼ |
| Q2-2025 | $32.04M ▼ | $55.74M ▲ | $-28.6M ▼ | $83.15M ▲ | $112.91M ▲ | $42.12M ▲ |
| Q1-2025 | $109.68M ▲ | $12.55M ▲ | $-20.39M ▲ | $-5.84M ▼ | $-12.88M ▲ | $-10.82M ▲ |
| Q4-2024 | $-66.97M ▼ | $-39.2M ▲ | $-31.05M ▼ | $4.3M ▼ | $-66.85M ▼ | $-70.25M ▲ |
| Q3-2024 | $-11.39M | $-71.64M | $22.75M | $155.83M | $107.33M | $-85.46M |
CEO
Vilhelm Robert Wessman
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public June 16, 2022
Method of going public SPAC
Full time employees 1,012
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 4
Debt To Equity 1
Price To Earnings 3
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
OAKTREE CAPITAL MANAGEMENT LP
Shares:4.67M
Value:$2.38M
SERENGETI ASSET MANAGEMENT LP
Shares:400K
Value:$204K
LINDEN ADVISORS LP
Shares:252.88K
Value:$128.97K
Summary
% Of Shares Owned 1.84%
Total Number Of Holders 14
Showing Top 3 of 14